Polpharma Pharmaceutical Works - API Manufacturer

drukuj

Research and Development   

We take full advantage of our own R&D function and facilities.
We also cooperate with external institutions.

 

Employees:
53 highly qualified professionals including 6 with doctoral degrees;
Structure:
Based on multidisciplinary teams carrying out their tasks according to the latest principles of project management
R&D Expenditure:
Over 10% of the annual revenue of the business unit
Facilities:
Process Maintenance and Improvement Laboratory and new Process Development Laboratory (lab and kilo lab scale); cGMP Pilot-Plant - Small Scale manufacturing facility
Competences:
- Wide network of Research and Development cooperating institutions (Universities, Institutes,Private Development Labs).
- Project Management and Resources Planning System
- Wide spectrum of processes and technologies available in-house and at the manufacturing sites of our business partners
- Experience in scale-up transfers and process improvements
- Proven quality of DMF documentation
Innovation focus:
- Breakthrough innovation - new API development
- Incremental innovation - improvement in the manufacturing processes of existing products

 

Patent Approach:
Respect for all third party intellectual property rights. Our own patent team is dedicated to designing and defending our processes.

 

We are experienced in designing new synthesis routes for producing APIs; our patent portfolio proves it.

 

Process for

Patent #

Registration date

piracetam PL 163254 Dec-90
glibenclamide PL 181213 Mar-96
salicylic acid PL 192178 Feb-99
sildenafil PL 195421
WO 0122918
Sep-99
alendronate sodium PL 195455 Jan-01
trandolapril PL 357762 Dec-02
lamotrigine PL 358816 Feb-03
gatifloxacine PL 364304 Dec-03
montelukast PL 370850
WO 2006070316
Oct-04
risedronate sodium PL 371958
WO 2006071128
Dec-04
aripiprazole PL 377893 Oct-05
carvedilol PL 382084
WO pending
Mar-07
montelukast PL 382346
WO pending
May-07

 

Latest news

CEP for Baclofen available

Monday, 02-01-2012
Polpharma has been granted Certificate of Suitability (CEP) by the European Directorate for the Quality of...

Polpharma – the most innovative company in Poland

Friday, 20-05-2011
Polpharma ranked first as the most innovative company in Poland, in a research study run by the Institute...

Polpharma has inaugurated a new state of the art 300 sq.m. Process Development Labs complex

Friday, 08-10-2010
Polpharma has inaugurated a new state of the art 300 sq.m. Process Development Labs complex for the...

Co-operation between Polpharma and RPG Life Sciences

Tuesday, 05-10-2010
RPGLS and Polpharma announced their co-operation in the development and manufacture of Active...
© POLPHARMA S.A. All rights reserved.
Realizacja: Ideo